2/n And first and most important is the patient: Teresa Barnes, a patient advocate, speaks about the unmet need of highly specific and effective therapies in IPF #PeopleILookUpTo #CureIPF #CurePF #MircroRNATherapies #Mir29 
3/n Rusty Montgomery @rmontonio of MiRagen: The Mir-29 mimic Remlarsen has hit fibrosis targets in a phase 1 trial of Keloid formation - a phase II trial is happening #AntiKeloid #CureScarring
4/n Mir-29 is significantly decreased in IPF lungs (Published) and circulating reduced expression of miR-29 correlates with reduced survival in patients with IPF (unpublished old data form my lab) #CurePF #MircroRNATherapies #Mir29
5/n Montgomery @rmontonio: Mir-29 mimics - both first generation (Remlarsen) and second generation (MRG-229) blunt fibrosis and fibrotic signatures in in-vivo mouse models, in-vitro cell culture models and ex-vivo precision cut human lung slices #CurePF #MircroRNATherapies #Mir29
6/n Most important from @rmontonio : You can deliver MRG-229 subcutaneously and get to the lung - no need for localized delivery #CureIPF #CurePF #MircroRNATherapies #Mir29
7/n What's next for mir-29? When will this go to humans? The answer is simple - need to assess safety. So far safety is MRG-229 is good in rats and mice. Next step is a large animal dose ranging toxicity study #SafetyFirst #CurePF #MircroRNATherapies #Mir29
8/n I really like this. industry/academia/government collaboration, started as a discussion at a Keystone conference, led a large @nih_nhlbi CADET grant & now a viable target for #CurePF & also makes sense based on our systems biology analyses insight.jci.org/articles/view/…
